Early life exposures and development of allergic disease in infants with familial risk: results from ongoing probiotic intervention trials

dc.contributor.authorPuisto Reetta
dc.contributor.authorTurta Olli
dc.contributor.authorRautava Samuli
dc.contributor.authorIsolauri Erika
dc.contributor.organizationfi=kliininen laitos|en=Department of Clinical Medicine|
dc.contributor.organization-code1.2.246.10.2458963.20.40612039509
dc.contributor.organization-code1.2.246.10.2458963.20.61334543354
dc.converis.publication-id176182792
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/176182792
dc.date.accessioned2022-10-28T13:44:19Z
dc.date.available2022-10-28T13:44:19Z
dc.description.abstract<p><strong>Aim:</strong> We search revision of risk determinants of the ongoing allergy epidemic.</p><p><strong>Methods:</strong> 433 children born to mothers with allergic disease or sensitization were selected from the three ongoing probiotic intervention trials for this case-control study. Children who developed atopic eczema or food allergy, had positive skin prick test results or had been prescribed inhaled corticosteroids by the age of two years were identified as cases (n=231) while children without allergic manifestations were the healthy controls (n=202). The data on early environmental exposures were collected from prospectively documented study records. The statistical analyses were adjusted for potential confounders.</p><p><strong>Results:</strong> Determinants associated with the increased risk of atopic eczema were lower maternal prepregnancy BMI (aOR 0.15, 95% CI: 0.037 – 0.54) and maternal intrapartum antibiotic treatment (aOR 2.21, 95% CI 1.20 – 4.10), the latter also linked to obstructive respiratory symptoms (aOR 3.87, 95% CI 1.07 – 14.06). The risk of allergic sensitization was associated with lower maternal prepegnancy BMI (aOR 0.18, 95% CI 0.43 – 0.79) and intrapartum antibiotic treatment (aOR 2.13, 95% CI 1.07 – 4.22).</p><p><strong>Conclusion:</strong> Based on our demonstrations, interventions such as personalized diets, can be optimized for specific subgroups and definite risk periods.<br></p>
dc.format.pagerange121
dc.identifier.eissn1651-2227
dc.identifier.jour-issn0803-5253
dc.identifier.olddbid183990
dc.identifier.oldhandle10024/167084
dc.identifier.urihttps://www.utupub.fi/handle/11111/44371
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/10.1111/apa.16518
dc.identifier.urnURN:NBN:fi-fe2022091258721
dc.language.isoen
dc.okm.affiliatedauthorPuisto, Reetta
dc.okm.affiliatedauthorTurta, Olli
dc.okm.affiliatedauthorRautava, Samuli
dc.okm.affiliatedauthorIsolauri, Erika
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3123 Gynaecology and paediatricsen_GB
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherWiley
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.doi10.1111/apa.16518
dc.relation.ispartofjournalActa Paediatrica
dc.relation.issue1
dc.relation.volume112
dc.source.identifierhttps://www.utupub.fi/handle/10024/167084
dc.titleEarly life exposures and development of allergic disease in infants with familial risk: results from ongoing probiotic intervention trials
dc.year.issued2023

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
Puisto_EtAl_2022_Early_life_exposures.pdf
Size:
432.16 KB
Format:
Adobe Portable Document Format